➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Baxter
McKesson
Express Scripts
Moodys

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Patent: 7,575,742

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,575,742
Title:Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
Abstract: Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.
Inventor(s): Martin; Roland (Bethesda, MD), McFarland; Henry (Gaithersburg, MD), Bielekova; Bibiana (Kensington, MD), Waldmann; Thomas (Silver Spring, MD)
Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services (Washington, DC) N/A (N/A)
Application Number:10/519,311
Patent Claims:see list of patent claims

Details for Patent 7,575,742

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   Start Trial The United States of America as represented by the Secretary of the Department of Health and Human Services (Washington, DC) N/A (N/A) 2022-06-28 RX Orphan search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17   Start Trial The United States of America as represented by the Secretary of the Department of Health and Human Services (Washington, DC) N/A (N/A) 2022-06-28 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 001 2002-03-07   Start Trial The United States of America as represented by the Secretary of the Department of Health and Human Services (Washington, DC) N/A (N/A) 2022-06-28 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07   Start Trial The United States of America as represented by the Secretary of the Department of Health and Human Services (Washington, DC) N/A (N/A) 2022-06-28 RX search
Novartis Pharms EXTAVIA interferon beta-1b INJECTABLE; SUBCUTANEOUS 125290 001 2009-08-14   Start Trial The United States of America as represented by the Secretary of the Department of Health and Human Services (Washington, DC) N/A (N/A) 2022-06-28 RX search
Biogen ZINBRYTA daclizumab INJECTABLE;INJECTION 761029 001 2017-05-26   Start Trial The United States of America as represented by the Secretary of the Department of Health and Human Services (Washington, DC) N/A (N/A) 2022-06-28 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
McKesson
Express Scripts
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.